Image

Europe Age-Related Macular Degeneration (AMD) Disease Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Europe
  • 350 Pages
  • No of Tables: 114
  • No of Figures: 33

Europe Age-Related Macular Degeneration (AMD) Disease Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Industry Trends and Forecast to 2029

Europe Age-Related Macular Degeneration (AMD) Disease Market

Market Analysis and Insights

Europe age-related macular degeneration (AMD) disease market is driven by the factors such as, rising geriatric population, increase in the prevalence of age-related macular degeneration (AMD) disease and pipeline products enhance its demand as well as rising investment in research and development leads to the market growth. Currently, healthcare expenditure has increased across developed and emerging countries that is expected to create a competitive advantage for manufacturers to develop new and innovative products.

Europe Age-Related Macular Degeneration (AMD) Disease Market

 

 

The prevalence of age-related macular degeneration, is expected to increase in developed countries due to the aging population and rising life expectancy. It is estimated that nearly 60% of patients have severe visual impairment occurring disease shortly after birth. This disease leads to blurring central vision in the patient’s eye. The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. However, the high cost associated with the treatment and procedure as well as stringent government regulations for product approval are expected to hamper the growth for age-related macular degeneration (AMD) disease market.

Europe age-related macular degeneration (AMD) disease market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Europe age-related macular degeneration (AMD) disease market will grow at a CAGR of 9.4% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Year

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million

Segments Covered

By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales)

Countries Covered

By Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2029

Market Players Covered

Novartis AG, PIXIUM VISION, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc, Gensight Biologics, Kodiak Sciences Inc. among others

Market Definition

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

Europe Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

  • Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the Europe incidence of early AMD. Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the Europe age-related macular degeneration (AMD) disease market growth.

  • Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the Europe age-related macular degeneration (AMD) disease market growth.

Opportunity

  •  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country Europe. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the Europe age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Europe age-related macular degeneration (AMD) disease market.

Restraint/Challenge

  • High cost of aesthetic surgical procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the Europe age-related macular degeneration (AMD) disease market growth.

Recent Developments

  • In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME. This will help the company to commercialize the product in the market in the forecast period.
  • In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.

Europe Age-Related Macular Degeneration (AMD) Disease Market Segmentation

Europe age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Dry AMD
  • Wet AMD

On the basis of type, the Europe age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD.

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

On the basis of end user, the Europe age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.

Distribution Channel

  • Retail Sales
  • Direct Tender

Age-Related Macular Degeneration (AMD) Disease Market

On the basis of distribution channel, the Europe age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.

Age-related Macular Degeneration (AMD) Disease Market Regional Analysis/Insights

The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.

The countries covered in the age-related macular degeneration (AMD) disease report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe.

Germany is expected to dominate due to increasing technological advancement in the developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Age-Related Macular Degeneration (AMD) Disease Market Share Analysis

Europe age-related macular degeneration (AMD) disease market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on age-related macular degeneration (AMD) disease market.

Some of the players in the market are Novartis AG, PIXIUM VISION, Bayer AG, Astellas Pharma Inc., Ionis Pharmaceutics, Johnson & Johnson Services, Inc, Gensight Biologics, Kodiak Sciences Inc. among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION

TABLE 2 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 EUROPE DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 8 EUROPE HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 14 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 16 EUROPE DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 18 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 20 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 21 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 22 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 23 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 24 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 26 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 27 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 28 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 29 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 30 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 32 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 33 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 34 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 35 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 36 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 38 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 39 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 40 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 41 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 44 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 45 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 46 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 47 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 48 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 50 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 51 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 52 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 53 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 54 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 56 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 57 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 58 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 59 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 60 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 62 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 63 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 64 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 65 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 66 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 68 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 69 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 70 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 71 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 74 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 75 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 76 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 77 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 80 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 81 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 82 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 83 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 85 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 86 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 87 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 88 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 89 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 90 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 92 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 93 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 94 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 95 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 96 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 98 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 99 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 100 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 101 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 102 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 104 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 105 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 106 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 107 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 108 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 110 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020- 2029 (USD MILLION)

TABLE 111 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020- 2029 (USD MILLION)

TABLE 112 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020- 2029 (USD MILLION)

TABLE 113 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 114 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions